NeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Sells $30,682.62 in Stock

by · The Markets Daily

NeuroPace, Inc. (NASDAQ:NPCE – Get Free Report) major shareholder Ltd. Kck sold 4,878 shares of NeuroPace stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $6.29, for a total value of $30,682.62. Following the transaction, the insider now directly owns 5,502,785 shares in the company, valued at approximately $34,612,517.65. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Ltd. Kck also recently made the following trade(s):

  • On Monday, October 21st, Ltd. Kck sold 3,720 shares of NeuroPace stock. The shares were sold at an average price of $6.10, for a total value of $22,692.00.
  • On Wednesday, October 16th, Ltd. Kck sold 6,900 shares of NeuroPace stock. The shares were sold at an average price of $6.57, for a total value of $45,333.00.
  • On Monday, October 14th, Ltd. Kck sold 4,031 shares of NeuroPace stock. The shares were sold at an average price of $6.54, for a total value of $26,362.74.
  • On Friday, October 11th, Ltd. Kck sold 2,572 shares of NeuroPace stock. The shares were sold at an average price of $6.35, for a total value of $16,332.20.
  • On Wednesday, October 9th, Ltd. Kck sold 3,123 shares of NeuroPace stock. The shares were sold at an average price of $6.10, for a total value of $19,050.30.
  • On Monday, October 7th, Ltd. Kck sold 4,910 shares of NeuroPace stock. The shares were sold at an average price of $6.66, for a total value of $32,700.60.
  • On Thursday, October 3rd, Ltd. Kck sold 3,318 shares of NeuroPace stock. The shares were sold at an average price of $6.97, for a total value of $23,126.46.

NeuroPace Stock Performance

Shares of NPCE stock traded down $0.20 during trading hours on Tuesday, reaching $6.00. 5,141 shares of the company’s stock were exchanged, compared to its average volume of 95,523. The business has a fifty day moving average price of $7.04 and a 200-day moving average price of $8.31. The company has a quick ratio of 5.47, a current ratio of 6.37 and a debt-to-equity ratio of 5.97. The stock has a market capitalization of $172.61 million, a P/E ratio of -5.21 and a beta of 1.78. NeuroPace, Inc. has a fifty-two week low of $5.73 and a fifty-two week high of $18.15.

NeuroPace (NASDAQ:NPCE – Get Free Report) last issued its earnings results on Tuesday, August 13th. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.03. The business had revenue of $19.26 million during the quarter, compared to analyst estimates of $18.30 million. NeuroPace had a negative return on equity of 195.26% and a negative net margin of 41.63%. NeuroPace’s revenue was up 16.6% on a year-over-year basis. During the same period in the prior year, the company posted ($0.36) earnings per share. Analysts predict that NeuroPace, Inc. will post -1.08 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of NPCE. Rhumbline Advisers acquired a new position in shares of NeuroPace in the second quarter valued at $111,000. Financial Advocates Investment Management grew its position in NeuroPace by 50.0% in the second quarter. Financial Advocates Investment Management now owns 15,000 shares of the company’s stock valued at $113,000 after acquiring an additional 5,000 shares during the period. Hillsdale Investment Management Inc. bought a new stake in NeuroPace in the first quarter valued at $155,000. XTX Topco Ltd grew its position in NeuroPace by 56.1% in the second quarter. XTX Topco Ltd now owns 24,055 shares of the company’s stock valued at $182,000 after acquiring an additional 8,643 shares during the period. Finally, Bank of New York Mellon Corp bought a new stake in NeuroPace in the second quarter valued at $257,000. 78.83% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. Wells Fargo & Company lowered their price target on NeuroPace from $20.00 to $15.00 and set an “overweight” rating for the company in a research note on Wednesday, August 14th. Cantor Fitzgerald restated an “overweight” rating and issued a $18.00 target price on shares of NeuroPace in a report on Wednesday, August 14th. Finally, Morgan Stanley reduced their target price on NeuroPace from $9.50 to $8.00 and set an “equal weight” rating for the company in a report on Monday, July 15th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $14.00.

Get Our Latest Analysis on NPCE

NeuroPace Company Profile

(Get Free Report)

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.

Recommended Stories